More than half of lung cancer patients have KRAS or EGFR mutations42; however, there is no available effective cancer therapy for patients with KRAS-mutant lung cancer, in contrast to those with EGFR-mutant lung cancer. This evidence concerns the gene EGFR and lung cancer.